GeoVax Labs (NASDAQ:GOVX) Rating Reiterated by HC Wainwright

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They presently have a $8.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 175.86% from the company’s previous close.

GeoVax Labs Price Performance

GeoVax Labs stock opened at $2.90 on Tuesday. The firm has a 50 day moving average of $1.85 and a 200 day moving average of $2.69. GeoVax Labs has a 12-month low of $1.09 and a 12-month high of $10.24.

GeoVax Labs (NASDAQ:GOVX) last released its earnings results on Tuesday, May 14th. The company reported ($2.47) earnings per share (EPS) for the quarter. Sell-side analysts predict that GeoVax Labs will post -7.41 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in GeoVax Labs stock. Armistice Capital LLC purchased a new position in GeoVax Labs, Inc. (NASDAQ:GOVX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned about 91.38% of GeoVax Labs as of its most recent SEC filing. 6.09% of the stock is currently owned by hedge funds and other institutional investors.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.